Kura Oncology KURA Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kura Oncology's accretion (amortization) of discounts and premiums, investments?
- Kura Oncology (KURA) reported accretion (amortization) of discounts and premiums, investments of $900K in Q1 2026.
- How has Kura Oncology's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Kura Oncology's accretion (amortization) of discounts and premiums, investments decreased by 66.2% year-over-year, from $2.66M to $900K.
- What is the long-term trend for Kura Oncology's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Kura Oncology's accretion (amortization) of discounts and premiums, investments has grown at a 24.6% compound annual growth rate (CAGR), from -$4.39M to $8.49M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to net income resulting from the amortization of premiums or the accretion of discounts on debt securities held as investments. It reflects the systematic recognition of interest income over the life of the investment, adjusting the carrying value of the security toward its par value. Investors use this to reconcile reported net income with actual cash flows generated from investment portfolios.